Raymond James Maintains Outperform on AbbVie, Raises Price Target to $189
Portfolio Pulse from Benzinga Newsdesk
Raymond James analyst Gary Nachman maintains an Outperform rating on AbbVie (NYSE:ABBV) and raises the price target from $181 to $189.
February 05, 2024 | 12:24 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Raymond James maintains an Outperform rating on AbbVie and raises the price target from $181 to $189.
The increase in price target by a reputable analyst firm like Raymond James typically signals a strong bullish sentiment towards the stock, suggesting a positive short-term price movement.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100